Just back from the 2025 Society of Gynecologic Oncology Annual Meeting, Dr Kathleen Moore summarizes several exciting advancements in endometrial cancer treatment. One key highlight was the DUO-E study, which evaluated the addition of durvalumab and olaparib to chemotherapy for frontline metastatic endometrial cancer, showing progression-free survival (PFS) benefits across various molecular subgroups with notable ctDNA detection rates. Another promising study was on puxitatug samrotecan, an antibody-drug conjugate targeting B7-H4, which demonstrated a 35-38% response rate and median PFS of 7 months in a phase 1/2a expansion cohort for recurrent endometrial cancer.
Additionally, a phase 2 study of the combination of letrozole, abemaciclib, and metformin in estrogen receptor-positive recurrent endometrial cancer showed a 32% response rate, with specific efficacy in tumors lacking RB1 loss or cyclin E amplification. These presentations underscore the ongoing evolution of treatments for endometrial cancer, exploring both targeted therapies and endocrine-based approaches.
